Jeena Sikho Lifecare Limited Publishes Three New Chronic Kidney Disease Studies
Jeena Sikho Lifecare Limited has published three new case studies on chronic kidney disease management in academic journals, demonstrating significant patient improvements through integrated Ayurvedic treatments. The research shows measurable clinical outcomes including reduced blood urea levels from 230.86 mg/dL to 117.39 mg/dL and improved kidney function parameters across multiple patient cases.
*this image is generated using AI for illustrative purposes only.
Jeena Sikho Lifecare Limited has announced the publication of three new case studies focusing on chronic kidney disease (CKD) management through Ayurvedic interventions. The company filed an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on December 30, 2025, regarding these academic publications.
New Research Publications on Kidney Health
The three studies have been published in the International Journal of Ayurveda and Herbal Research and the Journal of Applied Science and Education. These publications represent a shift in focus from the company's previous research on liver health and diabetes to specialized kidney disease management.
| Study Focus: | Publication Details |
|---|---|
| Study 1: | Healing Kidneys: Approach to Manage CKD |
| Study 2: | Impact of Ayurvedic Therapies on CKD Function |
| Study 3: | Effect of Classical Ayurvedic Treatment in CKD |
| Journals: | International Journal of Ayurveda and Herbal Research, Journal of Applied Science and Education |
Clinical Outcomes and Patient Improvements
The case studies demonstrate significant improvements in patient outcomes across multiple parameters. The research involved patients with varying stages of CKD, including advanced cases with comorbidities such as hypertension, Type 2 diabetes, and coronary artery disease.
| Treatment Results: | Key Improvements |
|---|---|
| Blood Urea Reduction: | 230.86 mg/dL to 117.39 mg/dL (Case 1) |
| Creatinine Improvement: | 6.32 mg/dL to 5.17 mg/dL (Case 1) |
| Blood Pressure Control: | 180/100 to 150/70 mmHg |
| Symptom Relief: | Reduced pedal edema, improved appetite |
Comprehensive Treatment Approach
The studies showcase integrated treatment protocols combining Ayurvedic medicines, Panchakarma therapies, and lifestyle modifications. The research involved patients aged 50-57 years with varying durations of kidney disease, demonstrating the versatility of Ayurvedic interventions.
Key treatment components included specialized formulations such as Nefron Plus Capsules, CKD Tablets, and Renal Support Capsules, alongside traditional therapies like Basti, Shirodhara, and Abhyanga. The studies also emphasized the importance of dietary modifications and stress management techniques.
Research Team and Methodology
The publications were co-authored by Managing Director Acharya Manish Grover and a team of medical professionals including Dr. Gitika Chaudhary, Dr. Richa, Dr. Shivani Dhiman, Dr. Tanu Rani, Dr. Priyanka Biswas, Dr. Suyash Pratap Singh, and Dr. Shubham Badhan.
The research methodology involved comprehensive patient assessments, including Ashta-Vidh Pariksha (eight-fold examination), regular monitoring of vital parameters, and detailed documentation of treatment responses over extended periods.
Implications for Ayurvedic Medicine
These publications contribute to the growing body of evidence supporting Ayurvedic interventions in chronic disease management. The studies provide detailed documentation of treatment protocols, patient responses, and clinical outcomes, potentially influencing future research directions in integrative nephrology.
The research demonstrates the company's commitment to evidence-based Ayurvedic practice and its role in advancing scientific understanding of traditional medicine applications in modern healthcare settings.
15
